ATE337301T1 - Substituierte imide als tnf inhibitoren - Google Patents

Substituierte imide als tnf inhibitoren

Info

Publication number: ATE337301T1
Authority: AT; Austria
Prior art keywords: tnf inhibitors; substituted imides; imides; inhibitors; substituted
Prior art date: 1994-12-30

Application number

AT95940847T

Other languages

English (en)

Inventor

George Muller

Mary Shire

David I Stirling

Original Assignee

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-30

Filing date

1995-11-20

Publication date

2006-09-15

1995-11-20 Application filed by Celgene Corp filed Critical Celgene Corp

2006-09-15 Application granted granted Critical

2006-09-15 Publication of ATE337301T1 publication Critical patent/ATE337301T1/de

Links

150000003949 imides Chemical class 0.000 title abstract 2
229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 title 1
239000002451 tumor necrosis factor inhibitor Substances 0.000 title 1
GODXRDNLVMRFSG-GFCCVEGCSA-N 2-[(2r)-1-(3,4-dimethoxyphenyl)propan-2-yl]isoindole-1,3-dione Chemical group C1=C(OC)C(OC)=CC=C1C[C@@H](C)N1C(=O)C2=CC=CC=C2C1=O GODXRDNLVMRFSG-GFCCVEGCSA-N 0.000 abstract 1
206010006895 Cachexia Diseases 0.000 abstract 1
206010014824 Endotoxic shock Diseases 0.000 abstract 1
206010040070 Septic Shock Diseases 0.000 abstract 1
108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
230000010076 replication Effects 0.000 abstract 1
241001430294 unidentified retrovirus Species 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Virology (AREA)
Immunology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Steroid Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AT95940847T 1994-12-30 1995-11-20 Substituierte imide als tnf inhibitoren ATE337301T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/366,679 US6429221B1 (en)	1994-12-30	1994-12-30	Substituted imides

Publications (1)

Publication Number	Publication Date
ATE337301T1 true ATE337301T1 (de)	2006-09-15

Family

ID=23444039

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95940847T ATE337301T1 (de)	1994-12-30	1995-11-20	Substituierte imide als tnf inhibitoren

Country Status (19)

Country	Link
US (3)	US6429221B1 (de)
EP (1)	EP0800514B1 (de)
JP (1)	JP4118329B2 (de)
KR (2)	KR100466838B1 (de)
AT (1)	ATE337301T1 (de)
AU (1)	AU709719B2 (de)
CA (1)	CA2208671C (de)
CZ (1)	CZ203697A3 (de)
DE (1)	DE69535195T2 (de)
DK (1)	DK0800514T3 (de)
ES (1)	ES2271948T3 (de)
FI (1)	FI972709A7 (de)
HU (1)	HUT77124A (de)
NZ (1)	NZ297324A (de)
PL (1)	PL185361B1 (de)
PT (1)	PT800514E (de)
RU (1)	RU2162078C2 (de)
SK (1)	SK86897A3 (de)
WO (1)	WO1996020926A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5703098A (en) *	1994-12-30	1997-12-30	Celgene Corporation	Immunotherapeutic imides/amides
US5728844A (en) *	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic agents
EP0818439B1 (de) *	1996-07-02	1999-10-13	Nisshin Flour Milling Co., Ltd.	Imid derivate
NZ334148A (en) *	1996-08-12	2001-12-21	Celgene Corp	3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
US6429212B1 (en)	1996-08-16	2002-08-06	Ishihara Sangyo Kaisha Ltd.	Medicinal composition
EP0933360A1 (de) *	1997-12-22	1999-08-04	Pharmachemie B.V.	Synthese von Beta-lactamen
ES2138561B1 (es) *	1998-04-17	2000-07-01	Univ Madrid Complutense	Uso de los peptidos vip y pacap en el tratamiento del shock endotoxico en mamiferos.
US6667316B1 (en) *	1999-11-12	2003-12-23	Celgene Corporation	Pharmaceutically active isoindoline derivatives
US6808902B1 (en)	1999-11-12	2004-10-26	Amgen Inc.	Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6326388B1 (en) *	1999-12-21	2001-12-04	Celgene Corporation	Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
US8030343B2 (en) *	2000-06-08	2011-10-04	Celgene Corporation	Pharmaceutically active isoindoline derivatives
US7091353B2 (en)	2000-12-27	2006-08-15	Celgene Corporation	Isoindole-imide compounds, compositions, and uses thereof
US7320991B2 (en)	2001-02-27	2008-01-22	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health	Analogs of thalidomide as potential angiogenesis inhibitors
CN1518447A (zh) *	2001-04-23	2004-08-04	��Ǵ�ѧר��	作为抗血管生成剂的新的苯邻二甲酰亚胺模拟物的合成和评估
EP2295081B1 (de)	2001-06-26	2018-10-31	Amgen Inc.	Antikörper gegen OPGL
US7498171B2 (en)	2002-04-12	2009-03-03	Anthrogenesis Corporation	Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US20100129363A1 (en) *	2002-05-17	2010-05-27	Zeldis Jerome B	Methods and compositions using pde4 inhibitors for the treatment and management of cancers
EP2258363A1 (de) *	2002-05-17	2010-12-08	Celgene Corporation	Zusammensetzungen zur Behandlung von Krebs
CN1713905A (zh) *	2002-10-15	2005-12-28	细胞基因公司	用于治疗骨髓增生异常综合征的选择性细胞因子抑制药
US20040087558A1 (en) *	2002-10-24	2004-05-06	Zeldis Jerome B.	Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US7776907B2 (en) *	2002-10-31	2010-08-17	Celgene Corporation	Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
TW200501945A (en)	2002-11-06	2005-01-16	Celgene Corp	Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
MXPA05004777A (es) *	2002-11-06	2005-07-22	Celgene Corp	Metodos de uso y composiciones que comprenden farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de padecimientos mieloproliferativos.
EP1581205A1 (de) *	2002-11-18	2005-10-05	Celgene Corporation	Verfahren zur verwendung undzusammensetzungen umfassend(+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamid
NZ540546A (en) *	2002-11-18	2008-03-28	Celgene Corp	Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
BR0317885A (pt) *	2002-12-30	2005-12-06	Celgene Corp	Composto, isÈmeros s e r enantiomericamente puros do mesmo, composição farmacêutica e métodos de inibir pde4 e mmp, de modular a produção de tnf-alfa, de tratar ou prevenir mds, de tratar doença mieloproliferativa, angiogênese indesejada, câncer, uma doença, inflamação dos pulmões, depressão, distúrbio pulmonar obstrutivo crÈnico, doença inflamatória do intestino, dermatite atópica, psorìase, doença de crohn, artrite reumatóide, asma, eslcerose múltipla e doença cardìaca em um mamìfero e de tratar, prevenir ou controlar a sìndrome de dor regional complexa
US20040175382A1 (en) *	2003-03-06	2004-09-09	Schafer Peter H.	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
US7973057B2 (en)	2003-09-17	2011-07-05	The United States Of America As Represented By The Department Of Health And Human Services	Thalidomide analogs
US8952895B2 (en)	2011-06-03	2015-02-10	Apple Inc.	Motion-based device operations
US20050142104A1 (en) *	2003-11-06	2005-06-30	Zeldis Jerome B.	Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
US20060004043A1 (en)	2003-11-19	2006-01-05	Bhagwat Shripad S	Indazole compounds and methods of use thereof
WO2005078978A1 (ja)	2004-02-13	2005-08-25	Matsushita Electric Industrial Co., Ltd.	送信装置、受信装置及び無線通信方法
US20080213213A1 (en) *	2004-04-14	2008-09-04	Zeldis Jerome B	Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
MXPA06012279A (es) *	2004-04-23	2007-01-31	Celgene Corp	Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar.
CA2578789A1 (en)	2004-09-03	2006-03-16	Celgene Corporation	Substituted heterocyclic compounds and uses thereof
US20070190070A1 (en) *	2004-09-03	2007-08-16	Zeldis Jerome B	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
WO2006050057A2 (en) *	2004-10-28	2006-05-11	Celgene Corporation	Methods and compositions using pde4 modulators for treatment and management of central nervous system injury
US20080138295A1 (en) *	2005-09-12	2008-06-12	Celgene Coporation	Bechet's disease using cyclopropyl-N-carboxamide
EP2395995A1 (de)	2009-02-10	2011-12-21	Celgene Corporation	Anwendungsverfahren und zusammensetzungen mit pde4-modulatoren zur behandlung, prävention und management von tuberkulose
MX341050B (es)	2010-04-07	2016-08-05	Celgene Corp *	Metodos para tratar infeccion viral respiratoria.
EP2583098B1 (de)	2010-06-15	2018-08-08	Celgene Corporation	Biomarker zur behandlung von schuppenflechte
US8927725B2 (en)	2011-12-02	2015-01-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Thio compounds
WO2015175956A1 (en)	2014-05-16	2015-11-19	Celgene Corporation	Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
WO2017070291A1 (en)	2015-10-21	2017-04-27	Celgene Corporation	Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris)

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3536809A (en) *	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en) *	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en) *	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en) *	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) *	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US4215114A (en) *	1976-11-12	1980-07-29	The Upjohn Company	Analgesic N-[2-(furyl-methylamino and 2-thienylmethylamino)cycloaliphatic]be
IE58110B1 (en) *	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
SU1502568A1 (ru) *	1987-08-17	1989-08-23	Предприятие П/Я В-2343	Способ получени 6,7-диметокси-N-алкилфталимидинов
US5073543A (en) *	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) *	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) *	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) *	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) *	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
US5580578A (en) *	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
JPH0625163A (ja) *	1992-07-03	1994-02-01	Ube Ind Ltd	Ｎ−（ジメトキシベンジル）フタルイミド類およびその製造法
AU5165093A (en) *	1992-10-08	1994-05-09	E.I. Du Pont De Nemours And Company	Fungicidal and miticidal aminopyrimidines
US5591767A (en) *	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
US5629327A (en) *	1993-03-01	1997-05-13	Childrens Hospital Medical Center Corp.	Methods and compositions for inhibition of angiogenesis
US5541213A (en) *	1993-06-24	1996-07-30	Eisai Co., Ltd.	Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5698579A (en) *	1993-07-02	1997-12-16	Celgene Corporation	Cyclic amides
US5605914A (en) *	1993-07-02	1997-02-25	Celgene Corporation	Imides
US5463063A (en)	1993-07-02	1995-10-31	Celgene Corporation	Ring closure of N-phthaloylglutamines
DE69422306T4 (de) *	1993-11-30	2000-09-07	G.D. Searle & Co., Chicago	Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzündungen
IT1270594B (it) *	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5703098A (en) *	1994-12-30	1997-12-30	Celgene Corporation	Immunotherapeutic imides/amides
US5801195A (en) *	1994-12-30	1998-09-01	Celgene Corporation	Immunotherapeutic aryl amides
US5703092A (en) *	1995-04-18	1997-12-30	The Dupont Merck Pharmaceutical Company	Hydroxamic acid compounds as metalloprotease and TNF inhibitors
US5728844A (en)	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic agents
US5728845A (en)	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic nitriles
US5658940A (en) *	1995-10-06	1997-08-19	Celgene Corporation	Succinimide and maleimide cytokine inhibitors
US5635517B1 (en) *	1996-07-24	1999-06-29	Celgene Corp	Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en)	1996-07-24	2013-05-28	Celgene Corp	Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
DE122007000079I2 (de)	1996-07-24	2010-08-12	Celgene Corp	Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
US6281230B1 (en) *	1996-07-24	2001-08-28	Celgene Corporation	Isoindolines, method of use, and pharmaceutical compositions
US5798368A (en) *	1996-08-22	1998-08-25	Celgene Corporation	Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
NZ334148A (en) *	1996-08-12	2001-12-21	Celgene Corp	3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
HUP0003761A3 (en)	1997-07-31	2001-04-28	Celgene Corp Warren	Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
US5874448A (en) *	1997-11-18	1999-02-23	Celgene Corporation	Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) *	1997-11-18	1999-09-21	Celgene Corporation	Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
SE9803710L (sv)	1998-09-25	2000-03-26	A & Science Invest Ab	Användning av vissa substanser för behandling av nervrotsskador
US6020358A (en) *	1998-10-30	2000-02-01	Celgene Corporation	Substituted phenethylsulfones and method of reducing TNFα levels
CN1342146A (zh) *	1999-03-18	2002-03-27	塞尔基因公司	取代的1－氧代－和1,3－二氧代异吲哚啉及其在用于减少炎性细胞因子含量的药物组合物中的用途
US6667316B1 (en)	1999-11-12	2003-12-23	Celgene Corporation	Pharmaceutically active isoindoline derivatives
US6699899B1 (en)	1999-12-21	2004-03-02	Celgene Corporation	Substituted acylhydroxamic acids and method of reducing TNFα levels
US6326388B1 (en) *	1999-12-21	2001-12-04	Celgene Corporation	Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
US20030045552A1 (en)	2000-12-27	2003-03-06	Robarge Michael J.	Isoindole-imide compounds, compositions, and uses thereof

1994
- 1994-12-30 US US08/366,679 patent/US6429221B1/en not_active Expired - Fee Related
1995
- 1995-11-20 WO PCT/US1995/015384 patent/WO1996020926A1/en not_active Ceased
- 1995-11-20 HU HU9701849A patent/HUT77124A/hu unknown
- 1995-11-20 RU RU97112858/04A patent/RU2162078C2/ru not_active IP Right Cessation
- 1995-11-20 DE DE69535195T patent/DE69535195T2/de not_active Expired - Lifetime
- 1995-11-20 FI FI972709A patent/FI972709A7/fi unknown
- 1995-11-20 CA CA002208671A patent/CA2208671C/en not_active Expired - Fee Related
- 1995-11-20 PL PL95321065A patent/PL185361B1/pl not_active IP Right Cessation
- 1995-11-20 EP EP95940847A patent/EP0800514B1/de not_active Expired - Lifetime
- 1995-11-20 ES ES95940847T patent/ES2271948T3/es not_active Expired - Lifetime
- 1995-11-20 KR KR1019970704510A patent/KR100466838B1/ko not_active Expired - Fee Related
- 1995-11-20 SK SK868-97A patent/SK86897A3/sk unknown
- 1995-11-20 DK DK95940847T patent/DK0800514T3/da active
- 1995-11-20 NZ NZ297324A patent/NZ297324A/xx not_active IP Right Cessation
- 1995-11-20 CZ CZ972036A patent/CZ203697A3/cs unknown
- 1995-11-20 JP JP52098696A patent/JP4118329B2/ja not_active Expired - Fee Related
- 1995-11-20 KR KR10-2003-7016455A patent/KR20040007729A/ko not_active Ceased
- 1995-11-20 AT AT95940847T patent/ATE337301T1/de not_active IP Right Cessation
- 1995-11-20 PT PT95940847T patent/PT800514E/pt unknown
- 1995-11-20 AU AU42463/96A patent/AU709719B2/en not_active Ceased
2002
- 2002-03-25 US US10/105,833 patent/US6844359B2/en not_active Expired - Fee Related
2004
- 2004-11-16 US US10/989,945 patent/US7329761B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7329761B2 (en)	2008-02-12
DE69535195D1 (de)	2006-10-05
HUT77124A (hu)	1998-03-02
DE69535195T2 (de)	2007-07-12
FI972709A0 (fi)	1997-06-23
CA2208671A1 (en)	1996-07-11
EP0800514B1 (de)	2006-08-23
US6844359B2 (en)	2005-01-18
FI972709L (fi)	1997-08-29
AU709719B2 (en)	1999-09-02
KR100466838B1 (ko)	2005-09-02
SK86897A3 (en)	1998-01-14
NZ297324A (en)	2000-03-27
PT800514E (pt)	2006-12-29
RU2162078C2 (ru)	2001-01-20
US20050090516A1 (en)	2005-04-28
AU4246396A (en)	1996-07-24
JP4118329B2 (ja)	2008-07-16
KR980700968A (ko)	1998-04-30
WO1996020926A1 (en)	1996-07-11
HK1004674A1 (en)	1998-12-04
PL185361B1 (pl)	2003-04-30
FI972709A7 (fi)	1997-08-29
CA2208671C (en)	2009-02-10
JPH10511946A (ja)	1998-11-17
CZ203697A3 (en)	1997-11-12
KR20040007729A (ko)	2004-01-24
PL321065A1 (en)	1997-11-24
US6429221B1 (en)	2002-08-06
ES2271948T3 (es)	2007-04-16
DK0800514T3 (da)	2006-12-27
EP0800514A1 (de)	1997-10-15
US20020143027A1 (en)	2002-10-03

Legal Events

Date

Code

Title

Description

2007-06-15

UEP

Publication of translation of european patent specification

Ref document number: 0800514

Country of ref document: EP

2011-08-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE337301T1 (de)	2006-09-15	Substituierte imide als tnf inhibitoren
DE69522961D1 (en)	2001-10-31	Immunotherapeutische arylamide
PT862552E (pt)	2003-12-31	Succinimidas e maleimidas inibidoras de citocinas
ATE259787T1 (de)	2004-03-15	Inhibitoren des tumor-necrosis-factors
WO1995001348A3 (en)	1995-03-09	Imides as inhibitors of tnp alpha
NO996529D0 (no)	1999-12-28	Substituerte alkanohydroksamsyrer og metode for reduksjon av TNF<alfa>-nivåer
EA199700186A1 (ru)	1998-02-26	Новые дипептидные амидины, используемые в качестве ингибиторов тромбина
WO1998024763A3 (en)	1998-08-06	Immunotherapeutic imides/amides as pde iv and tnf inhibitors
NO986103L (no)	1998-12-23	Substituerte indazol-derivater og deres anvendelse som fosfodiesterase (PDE)type IV - og tumornekrose-faktor (TNF)inhibitorer
DK0726899T3 (da)	2000-06-26	Nye pyrazincarboxamidderivater, deres fremstilling og deres anvendelse i lægemidler
DK0944616T3 (da)	2003-09-29	Bicykliske arylcarboxamider og deres terapeutiske anvendelse
DK0797437T3 (da)	2001-06-05	Immunterapeutiske imider/amider samt anvendelse deraf til at reducere niveauer af TNFalfa
EP0683777A1 (de)	1995-11-29	Oxindol 1-(n-(alkoxycarbonyl)carboxamide und 1-(n-carboxamido)carboxamide als antiinflammatorische wirkstoffe.
GB8926611D0 (en)	1990-01-17	Compound and its use
DK1308444T3 (da)	2006-09-18	Substitueret 2(2,6 dioxo-3-fluorpiperidin-3-yl)-isoindoliner og deres anvendelse til reduktion af TNFalfa-niveau'er
RU97111990A (ru)	1999-06-10	Обезболивающее и противозудное средство
SU1277584A1 (ru)	2006-12-20	1,1-Ди-[2-(2-фурил)4-оксохиназолинил-3]-этилиден, проявляющий противовоспалительную и анальгезирующую активность
KR930014978U (ko)	1993-07-27	휴대용 가스버너의 가스통 결합장치